Borregaard ASA: Repurchase of own shares
26.11.2024: Borregaard ASA (”Borregaard”, OSE ticker: BRG)
Reference is made to the stock exchange notice of 15 November 2024 where Borregaard announced the intent to repurchase up to 200,000 of its outstanding common stock. The repurchase of shares will be conducted in a period from 18th November up to and including 20th December 2024 at the latest.
Borregaard has in the period from 18 November up to and including 26 November 2024 in total purchased 109,396 own shares through broker at an average price of NOK 183.25 per share.
Aggregated overview of transactions per day:
| Date | Aggregated daily volume (number of shares) | Weighted average share price per day (NOK) | Total daily transaction value (NOK) |
| 18.11.2024 | 15,628 | 181.4618 | 2,835,885.01 |
| 19.11.2024 | 15,628 | 182.4254 | 2,850,944.15 |
| 20.11.2024 | 15,628 | 183.1008 | 2,861,499.30 |
| 21.11.2024 | 15,628 | 181.9900 | 2,844,139.72 |
| 22.11.2024 | 15,628 | 183.8243 | 2,872,806.16 |
| 25.11.2024 | 15,628 | 186.9631 | 2,921,859.33 |
| 26.11.2024 | 15,628 | 183.0128 | 2,860,124.04 |
| Previously disclosed buys under the programme (accumulated) | n.a. | n.a. | n.a. |
| Accumulated under the buy-back programme | 109,396 | 183.25 | 20,047,257.71 |
The issuer’s holding of own shares:
Following the completion of the above transactions, Borregaard owns a total of 358,175 of own shares, corresponding to 0.36% of Borregaard’s share capital.
Appendix:
A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.
Contact:
Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909
This information is subject to the disclosure requirements pursuant to Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 Article 2 section 3 and Section 5-12 of the Norwegian Securities Trading Act.
Attachment
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
- CorelDRAW 2026 Review: New Features and Workflow Updates for Designers and Print Professionals Highlighted by Expert Consumers
- TTW Announces the Top 50 Travel Solution Cards in the World for 2026
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share